Journal
ONCOLOGIST
Volume 15, Issue -, Pages 14-22Publisher
WILEY
DOI: 10.1634/theoncologist.2010-S4-14
Keywords
Hepatocellular carcinoma; Risk factors; Cirrhosis; Hepatitis B virus; Hepatitis C virus; Surveillance
Categories
Funding
- Sanofi-Aventis
- Salix
- Gilead
- Intercept
- Roche
- Uptodate
- Bayer HealthCare Pharmaceuticals
Ask authors/readers for more resources
Most patients with hepatocellular carcinoma (HCC) have liver cirrhosis, which develops following long periods of chronic liver disease. Cirrhosis is characterized by a decrease in hepatocyte proliferation, indicating an exhaustion of the regenerative capacity of the liver, and results in an increase in fibrous tissue and a destruction of liver cells, which may ultimately lead to the development of cancerous nodules. Half of all cases of HCC are associated with hepatitis B virus infection, with a further 25% associated with hepatitis C virus. Other risk factors for developing HCC include alcoholic liver disease, nonalcoholic steatohepatitis, intake of aflatoxin-contaminated food, diabetes, and obesity. There are multiple factors involved in the etiology of HCC, all of which have a direct impact on patient characteristics and disease course, and although a causative agent can often be identified, HCC remains an extremely complex condition associated with a poor prognosis. Additionally, the geographic variation in etiology means that information from different countries is needed in order to optimize surveillance methods and develop effective chemoprevention strategies. Unfortunately, there are still many gaps in our current understanding, and further research efforts are needed to fully elucidate the diverse mechanisms involved in the pathogenesis of HCC and offer optimal prevention strategies for those at risk. The Oncologist 2010; 15(suppl 4): 14-22
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available